Genelux (NASDAQ:GNLX) Announces Earnings Results

Genelux (NASDAQ:GNLX – Get Free Report) announced its earnings results on Monday. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03), Zacks reports.

Genelux Stock Up 4.2%

GNLX stock opened at $2.00 on Wednesday. The company has a market cap of $90.48 million, a price-to-earnings ratio of -2.27 and a beta of 0.68. The business has a fifty day simple moving average of $2.29 and a 200-day simple moving average of $2.64. Genelux has a 52 week low of $1.77 and a 52 week high of $5.89.

Analyst Ratings Changes

GNLX has been the subject of a number of analyst reports. Lucid Cap Mkts raised Genelux to a “strong-buy” rating in a report on Wednesday, September 16th. Benchmark reaffirmed a “speculative buy” rating on shares of Genelux in a research note on Tuesday, August 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a research note on Thursday, October 15th. Finally, Wall Street Zen upgraded Genelux from a “strong sell” rating to a “sell” rating in a research report on Tuesday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Genelux has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Read Our Latest Stock Report on GNLX

Insider Buying and Selling at Genelux

In other Genelux news, CEO Thomas Zindrick sold 34,463 shares of the business’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $2.67, for a total transaction of $92,016.21. Following the completion of the sale, the chief executive officer owned 1,226,427 shares of the company’s stock, valued at approximately $3,274,560.09. The trade was a 2.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Yong Yu sold 9,683 shares of the business’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $2.75, for a total value of $26,628.25. Following the sale, the insider directly owned 258,688 shares of the company’s stock, valued at approximately $711,392. This trade represents a 3.61% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 47,903 shares of company stock worth $126,320 over the last ninety days. Corporate insiders own 7.50% of the company’s stock.

Genelux Company Profile

(Get Free Report)

Genelux Corporation is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its research centers on engineered viruses designed to target and destroy cancer cells while stimulating an immune response against tumors. The company’s lead candidate is olvimulogene nanivacirepvec, also known as Olvi-Vec, an engineered vaccinia virus being studied in clinical trials for ovarian cancer and other solid tumors. Genelux is also advancing additional candidates based on its oncolytic virus platform.

Featured Stories

Earnings History for Genelux (NASDAQ:GNLX)

Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.